Latest for RET Fusion Cancer
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Label changeThe FDA approved a label update for GavretoFDA
More about RET Fusion Cancer
RET fusions are most frequently found in non-small cell lung cancer (1-2% of cases) and papillary thyroid cancer (7-12% of cases, higher in pediatric patients), and less commonly in other tumor types including colorectal, breast, and other cancers. Because RET fusions are actionable across tumor types, comprehensive genomic profiling is essential for identifying these patients.
Keep reading about RET Fusion Cancer
Selective RET inhibitors have transformed treatment. Selpercatinib (Retevmo, Eli Lilly) received regular FDA approval for RET fusion-positive NSCLC in September 2022. Its label now also reports the Phase 3 LIBRETTO-431 trial, in which first-line Retevmo kept the cancer from growing for a median 24.8 months against 11.2 months on chemotherapy with pembrolizumab.
On July 14, 2026 the FDA gave selpercatinib traditional approval for RET fusion-positive solid tumors of any type in adults and children 2 and older whose cancer grew after earlier treatment or who have no good alternative. In the 75 patients with tumors other than lung and thyroid cancer, 47% responded. Pralsetinib (Gavreto) received regular approval for RET fusion-positive NSCLC in August 2023 and also has accelerated approval for RET fusion-positive thyroid cancer in people 12 and older. Its label added a boxed warning for serious infections in December 2025.
These selective inhibitors have largely replaced older multikinase inhibitors and chemotherapy for RET fusion-positive cancers.
What are the symptoms of RET Fusion Cancer?
These are common symptoms of RET Fusion Cancer, and how strong they are varies from person to person.
- Symptoms depend on the tumor type and location
- For lung cancer: persistent cough, shortness of breath, chest pain, coughing up blood
- For thyroid cancer: a neck lump, hoarseness, difficulty swallowing
- Fatigue and unexplained weight loss
- Bone pain, headaches, or neurological symptoms if the cancer has spread
- Some RET fusion cancers are discovered incidentally on imaging
Who gets RET Fusion Cancer?
RET fusions in NSCLC tend to occur in younger patients (median age ~60), never-smokers or light smokers, and are slightly more common in women, though they can occur in anyone. RET fusion-positive papillary thyroid cancer can occur at any age.
No clear ethnic predisposition is established, though detection rates vary by how commonly genomic testing is performed. The fusion is a somatic (acquired) event, not inherited, distinguishing it from germline RET mutations that cause hereditary medullary thyroid cancer.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for RET Fusion Cancer?
There are currently 2 FDA-approved medications for RET Fusion Cancer.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for RET Fusion Cancer treatment
Charity funds and drugmaker programs for RET Fusion Cancer, checked at the source.
Every program and fund for RET Fusion Cancer, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for RET Fusion Cancer
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
The RET gene page lists every condition Orphanet links to the gene and the open trials that name it.
Finding labs...
Trusted RET Fusion Cancer resources
Reputable organizations and medical references for learning more about RET Fusion Cancer, including disease registries, foundation resources, and clinical guidelines.